Exact Sciences stock edges higher after solid growth and cautious outlook
Published on 09/07/2026 at 23:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Exact Sciences stock (ISIN US30063P1057) is trading slightly higher as investors continue to focus on the company’s growing revenue base in cancer diagnostics and its cautious path toward sustainable profitability as of September 7, 2026. Recent quarterly figures show continued double-digit growth in screening and precision oncology revenue, while management has reiterated a disciplined investment approach in research and marketing.
Revenue growth remains the core driver
According to recent earnings data for Exact Sciences, the company reported quarterly revenue of around USD 700 million in its most recent reported quarter, driven mainly by its Cologuard stool DNA screening test and precision oncology portfolio in the first half of 2026. This represented a solid double-digit increase compared with the prior-year quarter, when revenue had been closer to the mid-USD 500 million range, underscoring the company’s ability to expand its testing volumes and penetrate existing markets. While the exact split by segment varies by period, screening revenue remains the largest contributor, with precision oncology adding a growing share.
The company’s revenue momentum is supported by higher test volumes and an expanding physician and payer base. In the latest quarter, management indicated that growth was particularly strong in colorectal cancer screening, where Cologuard has continued to gain acceptance among primary care physicians and gastroenterologists. At the same time, the precision oncology segment, which includes multi-gene panels and liquid biopsy offerings, showed robust growth, albeit from a smaller base. For investors, the key point is that Exact Sciences is still achieving growth rates in the low- to mid-teens percentage range, with quarterly revenue rising by more than USD 100 million compared with the same period a year earlier.
Profitability improves but remains a work in progress
Despite strong top-line growth, Exact Sciences remains focused on improving profitability. In the most recent quarter, the company narrowed its net loss compared with the prior year, reflecting a combination of higher gross profit and tighter control of operating expenses. Operating margins improved by several percentage points year-on-year, as cost per test declined and scale efficiencies began to take hold. However, the company still reported a net loss for the period, and management continues to emphasize long-term investments in sales, marketing, and research and development to sustain its competitive edge.
Guidance for the current fiscal year indicates that Exact Sciences expects continued revenue growth, with full-year sales projected to rise by a high-teens percentage rate compared with the prior year. Management has also signaled that adjusted EBITDA margins should trend higher, supported by volume growth and efficiency measures. For investors, the quantified comparison between revenue growth and margin improvement is crucial: Exact Sciences is increasing its revenue base by more than USD 500 million over a multiyear period while gradually reducing its losses, suggesting a potential path toward breakeven in the coming years if growth and cost discipline are maintained.
Analyst views highlight upside and risks
Recent analyst commentary on Exact Sciences stock has remained broadly constructive but balanced. Several covering analysts have reiterated positive ratings on the shares, pointing to the company’s leading position in non-invasive colorectal cancer screening and its expanding precision oncology portfolio. Updated price targets in 2026 generally reflect expectations for continued double-digit revenue growth and improving profitability, though they also incorporate risks related to reimbursement, competitive offerings, and the broader macroeconomic environment for healthcare spending.
One of the key risks highlighted in current research is competitive pressure from alternative screening methods and new entrants in molecular diagnostics. Exact Sciences faces competition from traditional colonoscopy, fecal immunochemical tests, and emerging blood-based screening assays. Analysts note that while Cologuard benefits from strong brand recognition and a growing evidence base, payer decisions and clinical guideline updates could influence future volumes. Additionally, the company’s high level of spending on commercialization and R&D means that execution missteps or slower-than-expected adoption of new products could delay the timeline for achieving sustainable profitability.
Flagship product: Cologuard and broader test portfolio
Exact Sciences’ flagship product, Cologuard, remains at the center of the company’s growth story. The stool DNA test is designed to detect colorectal cancer and advanced adenomas and has become a widely used non-invasive alternative to colonoscopy for eligible patients. Test volumes have increased steadily in recent years as physicians become more familiar with the screening option and as awareness campaigns reach more patients. Cologuard is particularly important for the company’s revenue because it represents a significant portion of screening sales and provides a platform for recurring demand as patients repeat tests according to guideline-recommended intervals.
Beyond Cologuard, Exact Sciences has built a portfolio of precision oncology tests that analyze tumor genetics to help guide treatment decisions. These include multi-gene panels that can be used on tissue samples or in some cases as liquid biopsies. Revenue from these tests has grown as oncologists incorporate molecular profiling into routine care, though the segment remains smaller than screening. Over time, management aims to balance the portfolio such that precision oncology accounts for a larger share of total revenue, potentially diversifying the business and reducing reliance on any single product.
Stock performance and investor perspective
As of early September 2026, market data show that Exact Sciences stock is trading within its established 52-week range, with the share price roughly in the middle of that band. Compared with the low point of the past year, the current price represents a clear recovery, and the stock remains below its 52-week high, reflecting a mix of optimism and caution among investors. The company’s market capitalization has grown in tandem with its revenue expansion, and trading volume indicates continued active interest from institutional and retail shareholders.
For investors, the quantified comparison between current share price levels and the 52-week high is a useful gauge of sentiment: Exact Sciences stock has recovered a significant percentage from its lows but still trades at a discount to its peak, suggesting that the market is waiting for clearer evidence of sustained profitability and competitive resilience before fully rerating the shares. The next set of quarterly results and any updates to guidance or regulatory developments in cancer screening and diagnostics will therefore be closely watched. A continued combination of double-digit revenue growth and incremental margin improvement could support further upside, while any signs of slowing growth or rising costs would likely weigh on the stock.
Exact Sciences stock fact box
- Company: Exact Sciences Corporation
- ISIN: US30063P1057
- Ticker: EXAS
- Trading venue: Nasdaq
- Sector / Industry: Health Care / Biotechnology & Diagnostics
- Index membership: S&P 500
